Pharmidex joins London Mayor Boris Johnson's trade mission to US

January 6, 2015

Boris Johnson is heading to the United States on a six-day trade mission aimed at bolstering London's science and technology industries.

Mr Boris Johnson’s US Trade Mission

Mr Boris Johnson, the Mayor of London has recently been in the US trying to attract investment for British businesses. Mr Johnson is using the US trade mission to promote London's TechCity - which supports the cluster of technology firms based in east London - and MedCity, which was launched last year to support life sciences.

He looked to visit Harvard University’s Stem Cell Institute (HSCI) in an attempt to bring together collaborations between London and Boston life sciences. Mr Johnson said “'The United States is a hugely important trading partner for London, offering massive opportunities for investment in this country and for businesses wanting to expand internationally. I want London to capitalise on the great relationships we have in Boston, New York City and Washington DC”.

In Boston and New York, the Mayor was joined by senior business figures from London's tech and life science sectors including Dr Mo Alavijeh of Pharmidex.

For more information please see: http://www.bbc.co.uk/news/uk-england-london-31161270

< Older Post

Newer Post >

🌟 Pharmidex is proud to sponsor CamMedChem’25! 🌟

September 12, 2025

We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. 👉 We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!

Pharmidex Histology Services: Precision You Can Trust

September 8, 2025

At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology

🔬 Expanding our integrated capabilities in autoimmune research

September 3, 2025

At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.